Şunu aradınız:: οφαργάραπ (Yunanca - İngilizce)

οφαργάραπ λβ
cytochrome p450 enzymes:

οφαργάραπ επέλβ
crestor is contraindicated:

οφαργάραπ ιακ ςιεξίεδνετνΑ
in patients with severe renal impairment (creatinine clearance < 30 ml/ min). in patients with myopathy. in patients receiving concomitant cyclosporin. during pregnancy and lactation and in women of childbearing potential not using appropriate contraceptive measures.

οφαργάραπ λβ ςυοισάκυαΚ ςυοτ
oral contraceptive/ hormone replacement therapy (hrt):

οφαργάραπ λβ νώτε 4. 4
- renal impairment

οφαργάραπ λβ ςοχγελέ ςόκιδοιρεπ 4. 4
for excipients see 6.1.

οφαργάραπ λβ οτητίαραπα ιανίε νάε ςεδάµοδβε
the recommended start dose is 5 or 10 mg orally once daily in both statin naïve or patients switched from another hmg coa reductase inhibitor.

ησηγόλοµθαβ εµ αµοτά εσ οφαργάραπ ιακ ςιεξίεδνετνΑ
an assessment of renal function should be considered during routine follow-up of patients treated with a dose of 40 mg.

ΗΦΡΟΜ ΗΚΙΝΧΕΤΟΚΑΜΡΑΦ 6. 1. οφαργάραπ λβ αχοδκέ ατ
the use of crestor in patients with severe renal impairment is contraindicated for all doses.

οφαργάραπ επέλβ ησωπόκ ιακ ςογγιλί ςωπό υοκάµραφ υοτ ςειεγρένεραπ νύοτσιναφµε αν ότανυδ ιανίΕ (
the effects of overdose of lansoprazole in humans are not known (although the acute toxicity is likely to be low) and, consequently, instructions for treatment cannot be given.

οφαργάραπ επέλβ ησωπόκ ιακ ςογγιλί ςωπό υοκάµραφ υοτ ςειεγρένεραπ νύοτσιναφµε αν ότανυδ ιανίΕ (13: ήλοβοπα ιακ ςόµσιλοβατεΜ ςενΐετωρπ εσ ιατνούεµσεδ αίοπο ατ ακαµράφ.
lansoprazole is concentrated in the parietal cells and becomes active in their acidic environment, whereupon it reacts with the sulphydryl group of h+/ k+atpase causing inhibition of the enzyme activity.